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Nephrotoxicity is a common complication of cisplatin
chemotherapy that limits its clinical use. Here, we determined
whether arachidonic acid metabolism has a role in the
pathogenesis of cisplatin nephrotoxicity in mice. Three days
following cisplatin injection, wild-type mice displayed renal
functional and structural abnormalities consistent with
nephrotoxicity accompanied by elevated circulating and
renal levels of TNF-a and renal levels of IL-1b, subunits of
NADPH oxidase, thiobarbituric acid-reactive substances, and
PGE2. These indices of kidney injury, inflammation, oxidative
stress, and arachidonate metabolism were all diminished in
microsomal prostaglandin E synthase-1 (mPGES-1) null mice;
a phenotype recapitulated by treatment of wild-type mice
with the COX-2 inhibitor celecoxib. Following cisplatin
administration, there was paralleled induction of COX-2 and
mPGES-1 in renal parenchymal cells. Interestingly, mPGES-1
null mice were not protected from acute kidney injury caused
by ischemia–reperfusion or endotoxin. Hence, our results
suggest the activation of COX-2/mPGES-1 pathway in renal
parenchymal cells may selectively mediate cisplatin-induced
renal injury. This may offer a novel therapeutic target for
management of the adverse effect of cisplatin chemotherapy.
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Cis-diamminedichloroplatinum (cisplatin), an inorganic
molecule, is one of the simplest and most effective
chemotherapeutic agents and is widely used for treatment
of various types of solid tumors, including testicular, ovarian,
head, neck, and uterine cervical carcinoma and nonsmall cell
lung carcinoma.1–4 Unfortunately, its clinical use is limited by
severe side effects in normal tissues. Nephrotoxicity is a
frequent adverse effect with about 25–35% patients displaying
decline of renal function after a single dose of cisplatin.5
Despite intensive investigation, the mechanisms underlying
cisplatin-induced nephrotoxicity are not fully understood.
After administration, cisplatin is taken up in renal
tubular cells at high concentrations, leading to tubular
injury and cell death. The signaling mechanisms res-
ponsible for cisplatin-induced cytotoxicity appear to be
multifactorial, involving inflammation, oxidative stress, and
caspase.4
Prostaglandin E2 (PGE2), a major product of arachidonic
acid (AA) metabolism, has an established role in mediating
pain and inflammatory responses.6 The biosynthesis of PGE2
requires three sequential steps of the cyclooxygenase (COX)
pathway: the release of AA from membrane glyceropho-
spholipids by phospholipase A2, conversion of AA to the
unstable intermediate PGH2 by COX-1 or COX-2, and finally
isomerization of PGH2 to PGE2 by prostaglandin E synthase
(PGES).7,8 To date, at least three major forms of PGES have
been cloned and characterized: membrane-associated PGES
(mPGES)-1, mPGES-2, and cytosolic PGES.8 mPGES-1 is a
16-kDa membrane-bound protein encoded by a 2.0-kb
transcript. Similar to COX-2, mPGES-1 expression in
inflammatory cells is highly inducible in macrophages
in vitro9,10 and in the spleen and lung in vivo11–13 in response
to proinflammatory stimuli. Moreover, mPGES-1-deficient
mice exhibit blunted pain and inflammatory responses.9,14
mPGES-1 has also be implicated to have a key role in a
number of chronic inflammatory diseases.15 Owing to the
cardiovascular consequences of COX-2 inhibitors, mPGES-1
has been considered as a promising target for the next
generation of analgesic drugs. Here, we describe a novel role
of mPGES-1 and COX-2 in the pathogenesis of cisplatin
nephrotoxicity.
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RESULTS
mPGES-1 deletion attenuates cisplatin-induced renal
dysfunction and tubular damage
To investigate the role of mPGES-1 in cisplatin nephro-
toxicity, mPGES-1 wild-type (WT) and knockout (KO) mice
were subjected to cisplatin treatment and the severity of renal
dysfunction was reflected by blood urine nitrogen (BUN) and
plasma creatinine (Cr). At baseline, the values of BUN and
plasma Cr were similar between the genotypes. Cisplatin
treatment remarkably elevated BUN and plasma Cr in
WT mice. These increases were attenuated by 80% for plasma
Cr and 38% for BUN in the KO mice (Figure 1). Grossly, the
degree of kidney swelling secondary to cisplatin-induced
renal injury appeared similar between the genotypes
(Figure 2a) as confirmed by the similar increase in kidney
wet weight (WT: 0.283±0.027 vs 0.162±0.013 g, Po0.05;
KO: 0.279±0.023 vs 0.171±0.015 g, Po0.05). However,
following cisplatin treatment, the WT kidney became pale
and ischemic contrasting to the normal appearance of the KO
kidney (Figure 2a). Microscopically, at baseline, there was no
obvious difference in the renal morphology between the
genotypes. While, following cisplatin treatment, WT mice
displayed severe renal pathological changes characterized
by distortion of the overall renal morphology, dilation
of renal tubules, and appearance of protein cast, most of
which were significantly attenuated in the KO mice (Figure 2b).
The difference in the renal injury between the geno-
types was further reflected by the semiquantitative histolo-
gical damage score (Figure 2c). Acute renal failure is often
associated to fluid retention, leading to a fall in hematocrit.
We found that hematocrit significantly decreased in WT
mice after cisplatin treatment and this decrease was less in
the KO mice (Figure 3a). Interestingly, the body weight
loss, which reflects the general or gastrointestinal toxicity
of cisplatin, was not different between the genotypes
(Figure 3b).
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Figure 1 |Assessment of renal function after cisplatin treatment.
Blood urine nitrogen (BUN) (a) and plasma creatinine (Cr) (b) in
membrane-associated prostaglandin E synthase-1 (mPGES-1) þ /þ
and / mice at 72h following treatment with vehicle or cisplatin.
Wild-type (WT)/vehicle: N¼ 6; knockout (KO)/vehicle: N¼ 6; WT/
cisplatin: N¼ 16; KO/cisplatin: N¼ 16. Data are mean±s.e.
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Figure 2 |Morphological analysis of cisplatin-induced renal injury in membrane-associated prostaglandin E synthase-1 (mPGES-1)
þ /þ and / mice. (a) Gross kidney appearance. (b) Hematoxylin and eosin staining (magnification:  200 shown) of renal cortex.
(c) Renal injury score in cisplatin-treated mPGES-1 þ /þ and / mice. Wild-type (WT)/vehicle: N¼ 6; knockout (KO)/vehicle: N¼ 6;
WT/cisplatin: N¼ 9; KO/cisplatin: N¼ 10. N¼ 9 per group. Data are mean±s.e.
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mPGES-1 deletion attenuates cisplatin-induced
renal expression of cytokines
Activation of proinflammatory cytokine release is well known
to contribute to cisplatin nephrotoxicity.16 In particular,
tumor necrosis factor-a (TNF-a) is shown to have a central
role in the activation of the cytokine response in this disease
process.16 Therefore, our emphasis was placed on analysis of
the activation of TNF-a in response to cisplatin treatment.
Immunoblotting demonstrated a marked increase in the total
protein abundance of renal TNF-a in cisplatin-treated WT
mice and this increase was significantly attenuated in the
KO mice (Figure 4a). This result was confirmed at mRNA
level using quantitative reverse transcriptase (qRT)-PCR
(Figure 4b). Moreover, circulating TNF-a levels were
measured by using enzyme-linked immunosorbent assay.
Consistent with the gene expression data, the increases in
plasma TNF-a concentrations were less in the KO mice than
in WT controls (Figure 4c). Renal interleukin (IL)-1b mRNA
expression exhibited similar patterns of changes as TNF-a
(Figure 4d).
mPGES-1 deletion attenuates cisplatin-induced ROS
production
In addition to inflammation, oxidative stress is another
important factor involved in the pathogenesis of cisplatin
nephrotoxicity. Therefore, we evaluated the effect of mPGES-
1 deletion on cisplatin-induced oxidative stress. The level of
kidney thiobarbituric acid-reactive substances (TBARS), an
index of reactive oxygen species (ROS) generation, signifi-
cantly increased in WT mice after cisplatin treatment
and this increase was completely abolished in the KO mice
(Figure 5a). The increased ROS generation in cisplatin-
treated WT mice was associated with elevated renal expres-
sion of p47phox (Figure 5b) and gp91phox (Figure 5c), the two
major subunits of NADPH oxidase, but not NOX-1 (Figure
5d) or NOX-3 (Figure 5e). The stimulation of the expression
of p47phox and gp91phox was concomitantly suppressed in the
KO mice (Figure 5b and c). Cisplatin-induced oxidative stress
in WT mice was also associated with downregulation of
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Figure 3 | Effects of cisplatin-treatment on hematocrit (Hct) and
body weight. Changes in hematocrit (Hct) (a) and body weight (b)
in membrane-associated prostaglandin E synthase-1 (mPGES-1)
þ /þ and /mice following treatment with vehicle or cisplatin.
Hct was determined at 72 h following cisplatin treatment and
body weight was monitored daily. Wild-type (WT)/vehicle: N¼ 6;
knockout (KO)/vehicle: N¼ 6; WT/cisplatin: N¼ 9; KO/cisplatin:
N¼ 10. Data are mean±s.e.
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Figure 4 | The levels of proinflammatory cytokines in membrane-associated prostaglandin E synthase-1 (mPGES-1) þ /þ and /
mice following treatment with vehicle or cisplatin. (a) Immunoblotting of tumor necrosis factor-a (TNF-a) and a-tubulin in the kidney.
The densitometric value of TNF-a protein was normalized by a-tubulin. The mean values are shown below the immunoblot. *Po0.05 vs
control. (b) Quantitative reverse transcriptase (qRT)-PCR analysis of renal TNF-a. (c) Enzyme-linked immunosorbent assay analysis of
circulating TNF-a. (d), qRT-PCR analysis of renal interleukin (IL)-1b. Wild-type (WT)/vehicle: N¼ 6; knockout (KO)/vehicle: N¼ 6; WT/cisplatin:
N¼ 9; KO/cisplatin: N¼ 10. Data are mean±s.e.
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superoxide dismutase 2 (SOD2) and SOD3 with unchanged
SOD1 (Figure 5f–h), suggesting reduced antioxidant capacity.
The downregulation of SOD2 and SOD3 was completely
prevented in the KO mice (Figure 5f–h). Interestingly, renal
SOD3 expression was even upregulated in the KO mice after
cisplatin treatment (Figure 5h).
Assessment of apoptotic pathway
Apoptosis can be induced within a few hours of cisplatin
treatment in cultured renal proximal tubular cells and may
represent an early event in the pathogenesis of cisplatin
nephotoxicity.4 It has also been shown that the Bak/Bax
activation is a key element of the apoptotic pathway induced
by cisplatin.17 We compared renal mRNA expression of
Bak/bax as well as Bcl-2 between the genotypes after cisplatin
treatment. To our surprise, neither the induction of Bax/Bak
nor bcl-2 expression was affected in the KO mice (Figure 6).
These results revealed no evidence for changes in the
apoptotic pathway in mPGES-1 KO mice.
Activation of renal mPGES-1 by cisplatin treatment
At baseline, immunostaining detected a low level of
mPGES-1 immunoreactivity in the collecting duct. Cisplatin
treatment induced a marked, widespread upregulation of
mPGES-1 immunoreactivity in the kidney (Figure 7a). This
enhanced labeling was completely competed out with the
immune peptide, thus confirming specificity of the antibody.
The stimulation of renal mPGES-1 expression was further
confirmed by immunoblotting (Figure 7b) and qRT-PCR
(Figure 7c). In contrast, renal expression of mPGES-2
(Figure 7d) and cytosolic PGES (Figure 7e) was unaffected
by neither cisplatin treatment nor mPGES-1 deletion. We
measured kidney PGE2 content using enzyme-linked im-
munosorbent assay. At 72 h after cisplatin treatment, kidney
PGE2 content significantly increased in WT mice. This
increase was markedly blunted in the KO mice (Figure 7f).
Role of COX-2 in cisplatin nephrotoxicity
To investigate the role of COX-2 in cisplatin nephrotoxicity,
the COX-2 inhibitor celecoxib was used. celecoxib treatment
was started 72 h before cisplatin treatment. Cisplatin treat-
ment induced renal dysfunction (Figure 8a and b), renal
histological abnormalities (Figure 8c and d), and indices
of proinflammatory cytokines (Figure 9a–c) and oxidative
stress (Figure 9d–f), all of which were significantly attenuated
by celecoxib. Immunostaining detected a marked, widespread
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Figure 5 | Evaluation of oxidative stress after cisplatin treatment. Measurements of kidney thiobarbituric acid-reactive substances
(TBARS) (a) and quantitative reverse transcriptase (qRT)-PCR analysis of renal expression of p47phox (b) and gp91phox (c), NOX1 (d), NOX3 (e),
superoxide dismutase (SOD1) (f), SOD2 (g), and SOD3 (h) in membrane-associated prostaglandin E synthase-1 (mPGES-1) þ /þ and /
mice following treatment with vehicle or cisplatin. Wild-type (WT)/vehicle: N¼ 6; knockout (KO)/vehicle: N¼ 6; WT/cisplatin: N¼ 9; KO/
cisplatin: N¼ 10. Data are mean±s.e.
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induction of COX-2 immunoreactivity in the kidney
(Figure 10a), a pattern analogous to that of mPGES-1.
Consistent with this finding, qRT-PCR detected a sevenfold
stimulation of renal COX-2 mRNA expression (Figure 10b).
Kidney PGE2 content was significantly increased by cisplatin
and was almost completely normalized by celecoxib
(Figure 10c). To address the specificity of celecoxib, we
tested its effect on COX-1 activity in mice. A separate group
treated with indomethacin was used a positive control. Ex
vivo production of thromboxane B2 (TXB2) from the blood
was determined to reflect COX-1 activity from the platelets.
We found that TXB2 production was unaffected by celecoxib
treatment but was remarkably suppressed by indomethacin
treatment (vehicle: 13.76±1.38 ng/ml; celecoxib: 14.21±
1.75 ng/ml, P40.05 vs vehicle; indomethacin: 1.25±
0.71 ng/ml, Po0.01 vs vehicle; N¼ 5–7 per group). These
results suggested that the celecoxib treatment at the current
dose and duration did not affect COX-1 activity.
Role of mPGES-1 in other models of acute kidney injury (AKI)
To understand whether the renoprotective effect of mPGES-1
deletion was specific to the cisplatin model, we compared
renal ischemia–reperfusion (I/R) injury between mPGES-1
WT and KO mice (Figure 11). We found no difference in
BUN or plasma Cr between the genotypes after I/R injury.
Unexpectedly, renal mRNA expression of mPGES-1 along
with mPGES-2 and cytosolic PGES was significantly
decreased after I/R injury. Renal COX-2 expression tended
to be higher in the I/R vs sham group but this did not reach a
statistical significance. Subsequently, we examined endotox-
in-induced renal dysfunction in mPGES-1 KO mice.
Similarly, endotoxin-induced increases in BUN and plasma
Cr were not different between the genotypes nor was plasma
TNF-a level (Figure 12).
DISCUSSION
PGs have a pivotal role in mediating the inflammatory
response as highlighted by analgesic properties of nonster-
oidal anti-inflammatory drugs. PGE2 is one of the major
proinflammatory PG derived from the coordinated action of
COX-2 and mPGES-1. Similar to COX-2, mPGES-1 is
expressed at low level under baseline and can be induced
by proinflammatory stimuli and suppressed by corticoster-
oids.18 Studies, mainly from disruption of mPGES-1 gene in
mice, indicate the key roles of mPGES-1-derived PGE2 in a
number of pathological conditions, including chronic
inflammation, fever, pain, anorexia, atherosclerosis, stroke,
tumorigenesis, rheumatoid arthritis, osteoarthritis, and
myositis.15 So far, renal function of mPGES-1 has been
examined under physiological conditions, including low and
high salt intake,19–21 water loading,22 and angiotensin II
infusion,23 and angiotensin-converting enzyme inhibition;24
the majority of these studies support a physiological role of
mPGES-1 in regulation of sodium and water balance, and
blood pressure.25 However, little is known concerning
the pathological role of mPGES-1 in renal disease. To our
knowledge, this study is the first to demonstrate a role of
mPGES-1 in renal pathology in general and in the model of
cisplatin nephrotoxicity in particular. The pathological role
of mPGES-1 in cisplatin nephrotoxicity is demonstrated by
comparing renal functional and structural abnormalities, and
cytokine expression between mPGES-1 WT and KO mice at
72 h following cisplatin treatment. A single intraperitoneal
injection of WT mice with cisplatin (20 mg/kg) led to severe
renal failure (BUN and plasma Cr), renal tubular damage,
accompanied by marked induction of cytokine expression.
In contrast, the KO mice were largely resistant to cisplatin-
induced changes in renal function and structure, and
cytokine expression.
Inflammation is well recognized to have an important role
in cisplatin nephrotoxicity. Renal, circulatory, and urinary
levels of TNF-a, along with renal levels of other cytokines and
chemokines, including IL-1b, regulated upon activation
normal T cell expressed and secreted (RANTES), macro-
phage-inflammatory protein-2 (MIP2), monocyte chemotac-
tic protein-1 (MCP-1), and transforming growth factor-b1, are
upregulated by cisplatin administration.16,26 Importantly,
inhibition of TNF-a by pharmacological inhibitors or gene
knockout ameliorate cisplatin nephrotoxicity; the increases in
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Figure 6 |Assessment of apoptotic pathway after cisplatin
treatment. Quantitative reverse transcriptase (qRT)-PCR analysis
of renal Bak (a), Bax (b), and Bcl-2 (c) in membrane-associated
prostaglandin E synthase-1 (mPGES-1) þ /þ and / mice
following treatment with vehicle or cisplatin. Wild-type (WT)/
vehicle: N¼ 6; knockout (KO)/vehicle: N¼ 6; WT/cisplatin: N¼ 9;
KO/cisplatin: N¼ 10. Data are mean±s.e.
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cisplatin-induced increases in IL-b, transforming growth
factor-b, MCP-1 RANTES, and MIP1 are also blunted.16
Likewise, TNF-a is responsible for production of other
cytokines and chemokines, leading to inflammatory injury in
the kidney. Together, these findings establish a central role of
TNF-a in the pathogenesis of cisplatin renal injury. As
previously reported,16,26 we found remarkable increases of
circulating TNF-a and renal TNF-a mRNA and protein
expression in WT mice following cisplatin administration. In
contrast, these increases were significantly ameliorated in
mPGES-1 KO mice. It seems reasonable to speculate that
suppressing renal TNF-a expression may represent a primary
mechanism for the renoprotective effect of mPGES-1
deletion. Similar to TNF-a, renal IL-1b mRNA expression
in cisplatin-treated WT mice increased by sevenfold that was
almost completely blocked in mPGES-1 KO mice. Indeed,
TNF-a and IL-1b are often elevated in parallel, stimulate
production of each other, and act synergistically to stimulate
the production of other cytokines and chemokines.27
Abundant evidence suggests involvement of oxidative
stress in the pathogenesis of cisplatin nephrotoxicity. In this
regard, increased renal generation of ROS is demonstrated in
whole animal models and also in cultured renal tubular cells
after cisplatin administration. A large number of antioxidant
agents, including N-acetlcysteine, vitamin E, selenium,
dimethylthiourea, lecithinized SOD (L-SOD), cannabidiol,
melatonin and apocynin, and many others, are consistently
reported to protect against cisplatin nephrotoxicity.28–36
While, the sources of ROS generation during cisplatin
nephrotoxicity are still not well defined. We found that
cisplatin treatment significantly increased ROS generation in
the kidney as reflected by increased lipid peroxidation,
accompanied by increased renal expression of NADPH
oxidase subunits p47phox and gp91phox and decreased renal
expression of SOD2 and SOD3. These findings suggest that
the activation of NADPH oxidase together with reduced
antioxidant capacity may contribute to cisplatin-induced
oxidative stress. In support of our findings, the NADPH
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Figure 7 | Stimulation of renal membrane-associated prostaglandin E synthase-1 (mPGES-1) expression by cisplatin.
(a) Immunohistochemistry of mPGES-1 in the renal cortex of wild-type (WT) mice treated with vehicle or cisplatin. Specificity of the antibody was
validated by the using the competing mPGES-1 peptide. Arrow denotes the collecting duct (CD). Shown are representative photomicrographs
(hematoxylin and eosin staining; magnification:  200) from three independent experiments. (b) Immunoblotting analysis of renal mPGES-1 protein
expression in WTmice treated with vehicle or cisplatin. Immunoblotting of a-tubulin serves as a loading control. The densitometric value of mPGES-1
protein was normalized by a-tubulin. The mean values are shown below the immunoblot. *Po0.05 vs control. (c) Quantitative reverse transcriptase
(qRT)-PCR analysis of mPGES-1 in the kidneys of vehicle or cisplatin-treated mPGES-1 þ /þ and / mice. (d) qRT-PCR analysis of renal mPGES-2.
(e) qRT-PCR analysis of renal cytosolic PGES (cPGES). (f) Kidney prostaglandin E2 (PGE2) content in the two genotypes treated with vehicle or cisplatin.
PGE2 was determined by enzyme immunoassay and normalized by protein content. (b) N¼ 4–5 per group; (c–f) WT/vehicle: N¼ 6; knockout (KO)/
vehicle: N¼ 6; WT/cisplatin: N¼ 9; KO/cisplatin: N¼ 10. Data are mean±s.e.
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of renal p47phox. The gene expression was normalized by GAPDH. Control: N¼ 6; cisplatin: N¼ 12; cisplatinþ celecoxib: N¼ 8 per group.
Data are mean±s.e.
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oxidase inhibitor apocynin ameliorates cisplatin-induced
renal dysfunction and renal histological damage.35 We further
observed that mPGES-1 deletion remarkably attenuated
cisplatin-induced ROS generation and p47phox and gp91phox
expression, and restored SOD2 and SOD3 levels. However,
these findings are at odds with our previous observation that
PGE2 directly attenuates angiotensin II-induced ROS activa-
tion of NADPH oxidase in cultured vascular smooth muscle
cells.23 We suspect that the antioxidant effect of mPGES-1
deletion during cisplatin nephrotoxicity may be secondary to
the suppressed inflammatory response. Indeed, proinflam-
matory cytokines including TNF-a are well-known activators
of the NADPH oxidase system in macrophages as well as in
other noninflammatory cells.23,37
One of the most novel findings is the demonstration of the
specific pathogenic role of mPGES-1 in cisplatin nephro-
toxicity but not other types of AKI induced by I/R or
lipopolysaccharide (LPS). The mechanism underlying the
distinct responses of mPGES-1 KO mice to different insults is
unclear but could be related to the differences in the cellular
sources of cytokine production. Increased TNF-a production
in response to cisplatin treatment has been demonstrated in
renal epithelial cells in vitro, raising the possibility that renal
parenchymal cells may be a major source of TNF-a
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production in cisplatin nephrotoxicity.38,39 Zhang et al.40
elegantly employed bone marrow transplantation technique
to demonstrate that the production of TNF-a by parench-
ymal cells, rather than by bone marrow-derived infiltrating
immune cells, is responsible for cisplatin nephrotoxicity. On
the contrary, increasing evidence supports a primary role of
bone marrow-derived cells in the pathogenesis of renal
ischemic injury.41–43 A specific role of PGE2 in cisplatin-
induced renal injury can also be reflected by the differential
regulation of mPGES-1 and COX-2 in the two renal injury
models. The parallel induction of mPGES-1 and COX-2
following cisplatin treatment occurred predominantly in
renal proximal tubular cells, coinciding with the location of
TNF-a production. In contrast, renal expression of neither
mPGES-1 nor COX-2 was induced during I/R injury; renal
mPGES-1 expression was even downregulated. Likely, a
specific coupling between PGE2 and TNF-a induction in
renal proximal tubular cells may underlie the pathophysiol-
ogy of cisplatin nephrotoxicity. Similarly, mPGES-1 KO mice
were not protected against endotoxin-induced AKI. This
finding is surprising in light of the well-documented
proinflammtory role of mPGES-1.14 One explanation is that
like renal I/R injury, endotoxin-induced AKI may also be
chiefly mediated by bone marrow-derived cells. Although this
notion has not been directly assessed, infiltration of
leukocytes has been demonstrated in the septic kidney.44,45
It is interesting to note that the degree of body weight
loss after cisplatin treatment was not different between the
genotypes, suggesting that mPGES-1 may not mediate the
general or gastrointestinal toxicity of cisplatin. Moreover, we
found no difference in the degree of kidney swelling
indicative of the response to acute kidney injury. This
finding raises a possibility that mPGES-1 may have a role in a
particular stage, for example, the late rather than early stage
of the injury process. Apoptosis may represent an early event
in the pathogenesis of cisplatin nephrotoxicity.4 In cultured
renal proximal tubular cells, apoptosis is induced over a few
hours after exposure to cisplatin,46,47 and is preceded and
mediated at least in part by the Bak/Bax activation.17 We
found that neither the induction of Bax/Bak nor bcl-2
expression was affected in mPGES-1 KO mice. These results
suggest that mPGES-1 may act independently of the Bak/Bax
pathway, although other apoptotic pathways may still be
involved.
COX-2 inhibitors produce adverse effects on renal
function particularly during low salt intake in animals and
is occasionally associated with acute renal failures in humans,
highlighting the important role of this enzyme in renal
physiology.48,49 However, the role of COX-2 in renal
pathophysiology is poorly defined with conflicting reports
on detrimental50 vs beneficial51 effects of COX-2 inhibitors in
renal I/R injury. We found that renal COX-2 expression was
induced in parallel with mPGES-1 in renal parenchymal cells
following cisplatin administration. Importantly, the COX-2
inhibitor celecoxib ameliorated the cisplatin-induced renal
dysfunction and structural damage, recapitulating the
phenotype of mPGES-1 KO mice. Moreover, cisplatin-
induced increases in renal PGE2 content and cytokine
expression were similarly suppressed by celecoxib. The similar
beneficial effects produced by the COX-2 inhibitor and
mPGES-1 deletion substantiate the important role of
proinflammatory PGE2 in mediating cisplatin-induced renal
injury. However, our results do not agree with the study by
Greene et al.52 who found no beneficial effect of the COX-2
inhibitor SC236 on cisplatin nephrotoxicity in rats. The
reason for the discrepancy is unclear but could be related to
the differences in experimental protocols or animal species.
For example, the COX-2 inhibitors were administered at 72 h
(our study) vs 2 h (Greene’s study) before cisplatin treatment.
The efficacy of COX-2 inhibition as reflected by suppression
of tissue PGE2 production was validated in our but not
Greene’s study. More perplexing is that another COX-2
inhibitor nimesulide produced a worsening effect on
cisplatin-induced nephrotoxicity in spontaneously hyperten-
sive rats.53 This phenomenon may highlight the antihyper-
tensive and renal protective role of renal COX-2 in
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hypertension.54,55 In contrast, salicylate reduces cisplatin
nephrotoxicity in mice via inhibition of TNF-a,39 an effect
similar to that of celecoxib in this study. The mechanism by
which salicylate protects against cisplatin nephrotoxicity
remains unclear and may involve inhibition of nuclear factor-
kB or COX-2 or both. The definitive role of COX-2 in cisplatin
nephrotoxicity needs to be tested by using COX-2 KO mice.
Clinical trials demonstrate that regular use of nonsteroidal
anti-inflammatory drugs reduces the risk of developing
colorectal cancer by up to 40–50%.56 A large body of
experimental evidence has established a critical role of COX-2
in tumorigenesis with the proven antitumorigenic activity of
COX-2 inhibitors.57 Among COX-2-derived products, PGE2
has received particular attention because of its direct role in
the malignant progression of most solid tumors, including
colon, breast, lung, head neck, uterus, and stomach
carcinomas.58 Increasing evidence suggests involvement of
mPGES-1 in tumor promotion.13,59–61 More importantly,
mPGES-1 deletion results in marked suppression of intestinal
carcinogenesis in mice.62 In light of the antitumorigenic
activity of COX-2 and mPGES-1 inhibitors together with
their additional beneficial effects on cisplatin nephrotoxicity,
we suspect that the combination of either COX-2 or mPGES-1
inhibitor with the cisplatin may not only enhance the
chemotherapeutic potential in solid tumors but may also
minimize nephrotoxic effect of cisplatin. In support of this
notion, administration of CS-706, a selective COX-2
inhibitor, in combination with cisplatin completely regressed
the tumors in a mouse model of colorectal adenocarcinoma,
contrasting with the modest effect of a single treatment with
either drug.63
In summary, this study examined the role of COX-2/
mPGES-1 pathway in a mouse model of cisplatin nephro-
toxicity. Following cisplatin administration, the expression of
COX-2 and mPGES-1 was induced in parallel in renal
parenchymal cells. mPGES-1 KO mice were resistant to
cisplatin-induced renal dysfunction and structural damage,
accompanied with suppressed cytokine expression and
oxidative stress. The phenotype was recapitulated with the
COX-2 inhibitor celecoxib. Overall, intervention of COX-2/
mPGES-1 pathway in cisplatin-treated patients may offer a
novel approach for management of the renal toxicity with
added values of enhanced chemotherapeutic potential.
MATERIALS AND METHODS
Animals
mPGES-1 null mice were originally generated in DBA/1lacJ
background by Trebino et al.9 Owing to breeding difficulty, the /
mice were crossed with C57/BL6 129/SV mice and have been
maintained in a mixed DBA/1lacJC57/BL6 129/SV background
for more than 20 intercrosses. The / mice were bred using
homozygous females to homozygous males. Nonlittermate WT mice
on the same genetic background were used as controls. Male mice
(3–4 months old) were used for all experiments. All protocols
employing mice were conducted in accordance with the principles
and guidance of the University of Utah Institutional Animal Care
and Use Committee.
Cisplatin treatment of animals
Cisplatin was freshly prepared in saline at 1 mg/ml and injected
intraperitoneally into mPGES-1 WT and KO mice at a dose of
20 mg/kg; control group was administered with an equal volume of
saline. After 72 h, the animals were killed. To test the effect of the
COX-2 inhibitor celecoxib on cisplatin nephrotoxicity, celecoxib was
administered to mPGES-1 WT mice via daily gavage at 50 mg/kg/
day, starting at 72 h before cisplatin injection.
Effect of celecoxib on COX-1 activity
Thromboxane A2 (TXA2) is rapidly hydrolyzed nonenzymatically to
form TXB2, which is then quickly metabolized (t1/2¼ 5–7 min). The
ex vivo production of TXB2 in blood samples has been used as an
index of COX-1 activity.64 To address the specificity of celecoxib, we
examined its effect on COX-1 activity in comparison with
indomethacin. Briefly, mPGES-1 WT mice were administered with
vehicle, celecoxib (50 mg/kg/day), or indomethacin (2 mg/kg/day)
via daily gavage for 5 days. The blood samples were taken via
venipuncture and incubated at room temperature for 45 min, and
then centrifuged at 2000 g at 4 1C for 5 min. The serum TXB2 level
was measured by an enzyme immunoassay kit (Cayman Chemicals,
Ann Arbor, MI, USA).
Generation of mouse models with I/R and endotoxin-induced
renal injury
mPGES-1 WT and KO mice were subjected to renal I/R injury as
previously described.65 Briefly, under general anesthesia, the left and
right renal arteries were located, isolated, and occluded for 30 min
using microaneurysm clips to produce ischemia. After removing the
clips, verifying reperfusion, and closing the incision in two layers,
anesthesia was terminated and 1 ml of 37 1C saline was injected into
the abdomen to supplement fluid loss. A sham-operated group
underwent identical surgical procedures except that microaneurysm
clamps were not applied. In separate experiments, mPGES-1 WT
and KO mice were treated with a single intraperitoneal injection
of vehicle or LPS at 10 mg/kg (Escherichia coli 0127:B8 (Sigma,
St Louis, MO, USA); dissolved in saline). At 24 h after I/R or LPS
injection, blood and kidney samples were harvested for evaluation of
renal function and renal gene expression.
Immunohistochemistry
Kidneys from vehicle or cisplatin-treated mice were fixed with 4%
paraformaldehyde and embedded in paraffin. Kidney sections
(4-mm thickness) were incubated in 3% H2O2 for 10 min at room
temperature to block endogenous peroxidase activity. The slides
were boiled in antigen retrieval solution (1 mmol/l Tris-HCl,
0.1 mmol/l EDTA, pH¼ 8.0) for 15 min at high power in a
microwave oven. The sections were incubated overnight at 4 1C
with primary antibodies at appropriate dilutions (rabbit anti-
mPGES-1 and rabbit anti-COX-2 antibodies, Ann Arbor Cayman
Chemicals). After washing with phosphate-buffered saline, the
secondary antibody was applied and the signals visualized using the
ABC kit (Santa Cruz Biotechnology, CA, USA).
Immunoblotting
The whole kidney was lysed and protein concentration was
determined by Coomassie reagent. Protein (60 mg) from whole
kidney lysates were denatured in boiling water for 10 min, separated
by SDS-polyacrylamide gel electrophoresis, and transferred onto
nitrocellulose membranes. The blots were blocked overnight with
5% nonfat dry milk in Tris-buffered saline (TBS), followed by
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incubation for 1 h with rabbit anti-mPGES-1 at a dilution of 1:1000.
After being washed with TBS, blots were incubated with a goat
anti-horseradish peroxidase-conjugated secondary antibody (1:1000
dilution) and visualized with ECL kits (Amersham, Piscataway, NJ
USA).
qRT-PCR
Total RNA isolation and reverse transcription were performed as
previously described.19 Oligonucleotides were designed using
Primer3 software (available at http://frodo.wi.mit.edu/primer3/)
and the sequences are shown in Table 1. qPCR amplification was
performed using the SYBR Green Master Mix (Applied Biosystems,
Warrington, UK) and the Prism 7500 Real-Time PCR Detection
System (Applied Biosystems, Foster City, CA, USA). Cycling
conditions were 95 1C for 10 min, followed by 40 repeats of 95 1C
for 15 s, and 60 1C for 1 min.
Renal function and histology
Plasma Cr and BUN were determined to reflect renal function. For
histology, kidneys were fixed with 4% paraformaldehyde and stained
with hematoxylin and eosin. Tissues damage was indicated by
tubular lysis, dilation, disruption, and cast formation. The degree of
tissue damage was scored based on the percentage of damaged
tubules as previously described: 0, no damage; 1,o25%; 2, 25–50%;
3, 50–75%; 4, 475%.66
Enzyme immunoassay
The whole kidney was homogenized in phosphate-buffered saline
and then centrifuged for 5 min at 10,000 r.p.m. The supernatant was
diluted 1:50 with enzyme immunoassay buffer. Concentrations of
PGE2 were determined by enzyme immunoassay (Cayman Chemi-
cals) and normalized by protein concentrations. The plasma TNF-a
level was determined by using another enzyme immunoassay kit
(catalog number: 559732, BD OptEIA, BD Bioscience, San Jose, CA,
USA) according to the manufacturer’s instructions.
Measurement of TBARS
The measurement of TBARS in the mouse kidney was based on the
formation of malondialdehyde by using a commercially available
TBARS Assay kit (catalog number: 10009055, Cayman Chemical)
according to the manufacturer’s instructions.
Statistical analysis
The data are reported as means±s.e. Statistical significance was
assessed by unpaired, two-tailed Student’s t-tests for single
comparisons or analysis of variance for multiple comparisons.
Differences were considered to be significant when the probability
value was o0.05.
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